Warp Sciences launches drug development AI startup with $215 million funding
After leading OpenAI's AI-for-science efforts, Kevin Weil is launching a new company focused on accelerating a critical step in drug development with artificial intelligence. The startup, Warp Sciences, is emerging from stealth with fresh backing that underscores continued investor appetite for AI applications in biotechnology.
Highlights
- Warp Sciences launches from stealth with $215 million in funding, reaching a post-money valuation of $865 million as of Thursday.
- Lightspeed Venture Partners leads the fundraising round, alongside IVP, Premji Invest, and Lux Capital as major investors.
- Warp targets AI-driven drug development, reflecting increased investment in biotech tools to accelerate pharmaceutical research and efficiency.
Funding launch and company focus
As reported by Bloomberg, Warp Sciences is launching out of stealth with $215 million in funding and plans to announce the move on Thursday.Lightspeed Venture Partners is leading the fundraising effort, with IVP, Premji Invest and Lux Capital also investing. According to the company, the round values Warp at $865 million after the new money.
Biotech AI investment momentum
The new venture is targeting a key stage of drug development, positioning itself at the intersection of artificial intelligence and biotechnology. That focus places Warp in a segment where investors are backing tools designed to shorten research timelines and improve the efficiency of pharmaceutical development.Weil's move from OpenAI into a dedicated drug development startup also highlights how senior AI executives are increasingly building companies around industry-specific applications, rather than general-purpose models alone.
Our earlier article on AstraZeneca’s AI-driven drug discovery collaboration with insitro detailed a multi-year partnership targeting MASH and cardiomyopathies, including an upfront payment and potential milestone-based payouts. We noted how insitro’s “Virtual Human” platform is intended to help identify biological targets and move them toward development candidates, reflecting the broader push to use AI to accelerate and de-risk early research.
Latest Biotechnology News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
